BiotechTube
TumorGen

TumorGen

San Diego, United States· Est.
tumorgen.net
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $393K

Overview

TumorGen is a private, pre-clinical stage biotech targeting the root cause of cancer mortality: metastasis. The company is developing a proprietary drug discovery platform to identify compounds that disassociate metastatic cell clusters (MCCs), thereby stopping cancer spread. Led by a founder with a personal mission and a team combining scientific and financial expertise, TumorGen is positioning itself in a high-need, high-value oncology segment. Its business model is therapeutic, and it is currently pre-revenue, seeking investment and collaborations to advance its pipeline.

Oncology

Technology Platform

Proprietary drug discovery engine focused on identifying compounds that disassociate circulating metastatic cell clusters (MCCs) by targeting adhesion pathways.

Funding History

1
Total raised:$393K
Grant$393K

Opportunities

The primary cause of cancer death is metastasis, representing a vast, unaddressed market across multiple tumor types.
A successful therapy could be used as a universal adjuvant, creating a blockbuster opportunity.
Preventing late-stage cancer could also offer massive cost savings to healthcare systems, supporting favorable reimbursement.

Risk Factors

The science of targeting metastatic cell clusters is novel and high-risk, with no guarantee of clinical success.
As a pre-revenue, pre-clinical company, it is highly dependent on securing funding.
The regulatory pathway for an anti-metastatic adjuvant may require large, long, and expensive outcome trials.

Competitive Landscape

The field of metastasis prevention is competitive, with many large pharmaceutical and biotechnology companies investigating mechanisms like EMT inhibition, microenvironment modulation, and dormancy. TumorGen's specific focus on disrupting MCC adhesion is a niche approach, but it will compete for funding and ultimately market share with any therapy that improves metastatic outcomes.

More companies in Oncology (General) →More companies in United States →